HUTCHMED (China) Limited HCM
Set alert
At close · Oct 30
After hours · Oct 30, 4:02 PM ET
- YTD
- -1.35%
- 1 year
- -8.87%
- Open
- 13.26
- Prev close
- 13.59
- Mkt cap
- 2.29B
- Vol
- 33.49K
- Avg vol
- 66.77K
- EPS
- 0.10
- P/E
- 131.50
- Div yield
- 0.00%
More statistics
- Low
- 13.14
- High
- 13.42
- Forward P/E
- 50.73
- Beta
- 0.36
- Short ratio
- 4.66
- Inst. own
- 2.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 4, 2027
- 50-d avg
- 13.64
- 200-d avg
- 13.23
- 1y target
- 20.59
News
8 hours ago globenewswire.com
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
2 days ago globenewswire.com
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic…
-
4 days ago benzinga.com
Reported Earlier, HUTCHMED Says FDA Grants Orphan Drug Designation To Sovleplenib For Primary Immune Thrombocytopenia, Making It Eligible For 7 Years Of US Market Exclusivity
Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and…
4 days ago globenewswire.com
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this…
6 days ago gurufocus.com
Firms in Asia Pacific Embrace Unified Workday Platforms
Organizations across Asia Pacific are replacing fragmented legacy finance and human capital management (HCM) environments with a connected Workday platform that
6 days ago globenewswire.com
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with…
6 days ago gurufocus.com
AI Brings U.S. Enterprises More Value from Workday
Enterprises in the U.S. are asking Workday service providers to support AI adoption, platform expansion and continuous optimization to make finance and human ca
-
6 days ago benzinga.com
HUTCHMED Highlights SANOVO Phase III Data At ESMO, ORPATHYS Plus TAGRISSO Cuts Progression Or Death Risk 44% In First-Line EGFR-Mutated Lung Cancer, Improves OS; China Supplemental NDA Planned
— ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS…
1 week ago globenewswire.com
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
-
1 week ago benzinga.com
HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus…
1 week ago globenewswire.com
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO ® —
1 week ago globenewswire.com
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study…
1 week ago globenewswire.com
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its…
1 week ago seekingalpha.com
Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product
Braveheart Bio is undervalued as a late-stage HCM player, with two Phase 3 programs fully funded and a differentiated molecule for non-obstructive HCM. BRVE holds $527M in pro forma cash, supporting…
2 weeks ago defenseworld.net
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has received an average rating of "Moderate Buy" from the six analysts that are currently covering the firm, Marketbeat reports.…
4 weeks ago 247wallst.com
ADP Warns of Cooling Labor Market While Its Own Business Feels the Chill
ADP publishes the jobs data Wall Street watches every month, but its own payroll counts now tell a different story about where the labor market is actually heading.
1 month ago seekingalpha.com
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. LXRX anticipates NDA resubmission for ZYNQUISTA in T1D by Q4 2026, contingent on STENO1…
-
1 month ago benzinga.com
Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial
Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —Application…
1 month ago reuters.com
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday Anglo-Swedish drugmaker AstraZeneca had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in…
1 month ago globenewswire.com
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —
1 month ago globenewswire.com
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has…
1 month ago globenewswire.com
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from…
1 month ago gurufocus.com
New 3Sixty Insights Analysis Reinforces the Importance of Insperity's HRScale Service-Enabled HR Solution
[url="]Insperity, Inc.[/url] (NYSE: NSP), a leading provider of human resources and business performance solutions, today announced continued progress for the [
1 month ago marketbeat.com
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first…
1 month ago benzinga.com
HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript
HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For…
1 month ago gurufocus.com
Workday Named a Leader in Inaugural 2026 Gartner® Magic Quadrant™ for Workforce Management Technology
Workday Named a Leader in Inaugural 2026 Gartner Magic Quadrant⢠for Workforce Management TechnologyPR NewswirePLEASANTON, Calif., Sept. 17, 2026Workday Uni
1 month ago benzinga.com
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
1 month ago benzinga.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
2 months ago benzinga.com
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
-
2 months ago benzinga.com
HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a…
2 months ago benzinga.com
AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories
AstraZeneca announced positive Phase 3 lung cancer trial results and earned EU approval for its Enhertu breast cancer combination.
-
2 months ago benzinga.com
Reported Earlier, HUTCHMED Reports Late-Stage Results For New Lung Cancer Treatment Combo
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced…
2 months ago benzinga.com
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
-
2 months ago benzinga.com
Reported Sunday, HUTCHMED Says ORPATHYS Plus TAGRISSO Achieved Statistically Significant, Clinically Meaningful PFS And OS Improvements In MET-Driven EGFR-Mutated Lung Cancer
First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung…
-
3 months ago benzinga.com
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.09 per share. This is a 96.55 percent decrease over earnings of $2.61 per share from the same period last year. The company reported…
-
3 months ago benzinga.com
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.
-
3 months ago benzinga.com
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17
B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.
4 months ago benzinga.com
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial
HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.
-
4 months ago benzinga.com
Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase II Study For Intrahepatic Cholangiocarcinoma With FGFR2 Fusions
— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —— Fanregratinib holds promise as a new treatment option for…
-
4 months ago benzinga.com
Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile ——The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment…
-
5 months ago benzinga.com
HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration
Companies granted approval by the China National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior…
-
6 months ago benzinga.com
China Authority Accepts And Grants Priority Review To Hutchmed's Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia Patients Who Have Had An Insufficient Response To Prior Glucocorticoid Treatment
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application ("NDA") for sovleplenib for the treatment of adult patients with warm antibody autoimmune…
-
7 months ago benzinga.com
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20
B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.
-
7 months ago benzinga.com
HUTCHMED Recalls Cancer Drug Tazverik in China After US Withdrawal Over Safety Risks
HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc.…
-
8 months ago benzinga.com
HUTCHMED (China) FY EPS $2.62 Beats $1.43 Estimate, Sales $548.512M Miss $591.425M Estimate
HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.43 by 83.22 percent. This is a 1090.91 percent increase over earnings of…
8 months ago benzinga.com
An Overview of HUTCHMED (China)'s Earnings
An Overview of HUTCHMED (China)'s Earnings
-
9 months ago benzinga.com
Reported Earlier, HUTCHMED Reports Phase III SACHI Trial Published In The Lancet Demonstrating Improved PFS With Savolitinib Plus Osimertinib Versus Chemotherapy
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment.Savolitinib and…